Media

Strides Enters into a Strategic Product Development Partnership with Kenox to Expand Nasal Spray Portfolio for the US Market”

08 September, 2025

“Strides Delivers a Strong Q1FY26 with ₹11,197m Revenue, ₹2,181m EBITDA, and ₹1,140m Operational PAT”

29 July, 2025

Strides Delivers Strong FY25 Results, Exceeding Outlook Across All Metrics”

22 May, 2025

Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg

30 April, 2025

“Strides Pharma debuts with a stellar ESG rating of 76/100 in the S&P Global’s Corporate Sustainability Assessment (CSA) 2024”

22 January, 2025

Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets, 125 mg /250 mg, Expanding the Existing OTC Portfolio.”

20 January, 2025